ProQR Therapeutics N.V. News
Stocks to Watch and Trade During the Market Downturn
Knowing what's on your shopping list ahead of time is key to taking advantage of volatile markets.
Jensen: These Three Healthcare Stocks Are Worth a Look
Just because we're in the market's worst month of the year doesn't mean there aren't good investments available.
Lannett Scores FDA OK for Nexium Generic-Biotech Movers
Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.
ProQR cystic fibrosis drug passes first, early efficacy test
The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.
10 must-know biotech stock events to close out 2016
Important clinical trial results in Alzheimer's, cancer and Crohn's disease and a big FDA decision for Sarepta are expected before the end of the year.
Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments
Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.
Vertex Pharma To Start Next-Gen Cystic Fibrosis Drug Studies Earlier Than Expected
The company announced its 2015 business outlook on Sunday ahead of its presentation at the J.P. Morgan Healthcare Conference.
A New Take on the Big Mac (May Be) Headed to U.S. McDonald's Menus
This is very different than the Big Mac you know and love.
We're Enduring 'Housing Recession,' Homebuilders' Economist Says
The builder confidence index breached the break-even measure of 50 in August for the first time since May 2020.